世界の人工免疫調節療法市場(~2026):市場機会・臨床試験インサイト

◆英語タイトル:Artificial Immune Modulation Therapy Market Opportunity and Clinical Trials Insight 2026
◆商品コード:KUIK21FB015
◆発行会社(リサーチ会社):Kuick Research
◆発行日:2020年5月
◆ページ数:80
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Multi UserUSD6,000 ⇒換算¥684,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Kuick Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、世界の人工免疫調節療法市場について調査・分析を行い、概要、人工免疫調節プラットフォーム強化におけるナノテクノロジーの役割、合成免疫学、様々な疾患用人工免疫調節、独自の人工免疫調節プラットフォームのためのT細胞濃縮及び拡張(E+E)技術、人工免疫調節製品のNexImmune臨床試験、最近動向・機会、商業的機会、市場要因・課題、今後の方向性、競争状況などを掲載しています。
・概要
・人工免疫調節プラットフォーム強化におけるナノテクノロジーの役割
・合成免疫学
・様々な疾患用人工免疫調節
・独自の人工免疫調節プラットフォームのためのT細胞濃縮及び拡張(E+E)技術
・人工免疫調節製品のNexImmune臨床試験
・最近動向・機会
・商業的機会
・市場要因・課題
・今後の方向性
・競争状況
【レポートの概要】

“Artificial Immune Modulation Therapy Market Opportunity and Clinical Trials Insight 2026″ Report Highlights:

Immunotherapy Inspired Design for Artificial Immune Modulation (AIM)
Artificial Immune Modulations for Various Indications
Clinical Trial Insight for AIM: 3 Drugs
Expected Price Range for AIM Therapy: > US$ 250,000
Market Potential During Five Years of Commercialization: > USD 500 Million
Estimated Commercial Opportunity for Artificial Immune Modulation Drugs
Future Directions for Artificial Immune Modulation

The research report “Artificial Immune Modulation Therapy Market Opportunity and Clinical Trials Insight 2026” provides comprehensive insight on the applications of artificial immune modulation therapy in today’s cancer centric treatment methodologies. This report is focused towards introducing the therapy and the cells that are contributing to the therapy in an elaborated way. Report also discusses about the successful pre-clinical stage results of the therapy and information about its entry in the clinical trial landscape. The research report gives information about the growing interest of the researchers as well as companies towards the possible achievements that the therapy will face in the next few years.

Artificial Immune Modulation (AIM) is among the novel immunotherapy technologies that have been developed keeping in view the rising cases of cancer at global level. As every immunotherapy technology focuses on one major part of immune system, AIM technology’s working is also based on artificial antigen presenting cells (aAPC). AIM technology includes the engineering and administrating artificial antigen presenting cells to the patients which further is projected to mimic the core functions of natural antigen presenting cells present inside the human body.

The primary purpose with which artificial antigen presenting cells are administered to the patient involves antigen-specific recognition signal delivery by Major Histone Compatibility molecule loaded with an antigen peptide and also a co-stimulatory signal to direct action by the T cells. Development of another immunotherapy based treatment has caused an expansion of the field, where the contribution of immune cells against diseases is increasing exponentially. Targeting immune cells have projected a novel and regulated version of interaction between the diseased cells and immune system.

An important aspect of AIM therapy is that it provides satisfying nature for reinforcing the working mechanism of immune system against one target which includes the activation of specific types (antigen presenting cells and T-cells) in order to evoke a powerful immune response against specific antigen. It has been few decades since the development of immunotherapy for diseases in which immune system gets artificially activated, but few years since the discovery of AIM. Therefore, adding one more novel technology to this incredibly increases the access of eradicating cancer and other deadly cells from the body.

As per the research findings for analyzing the growing trends of artificial immune modulation, it has been observed that the therapy is prominent towards showing a data that is dominant. As the other immunotherapy products that are available for cancer such as Kymriah and Yescarta and their sales record establishes a hope that the arrival of novel products under AIM therapy will also establish a market that will be more inclined towards AIM. The growing cancer cases and the poor survival rate of other cancer therapies are driving the research world a little more dominant towards AIM.

Although the price of the therapy has not been decided yet but it has been estimated that the therapy will cost approximately the same as the other cancer immunotherapies. The therapy being novel is considered as a fast-growing method in the entire pharmaceutical industry. The therapy is still very young and is evaluated for causing a potential growth, substantive translational and clinical improvements. By observing the future outlook of the cancer cases and the current research activity, it is estimated that the market of AIM will undergo tremendous advancement leading towards the revolution of cancer therapeutics.

【レポートの目次】

1. Artificial Immune Modulation Nanotechnology Overview

1.1 Introduction to Artificial Immune Modulation Nanotechnology

1.2 Immunotherapy Inspired Design for Artificial Immune Modulation

1.3 Influence of Antigen Presenting Cells on T-cell Activation

2. Role of Nanotechnology in Enriching Artificial Immune Modulation Platform

2.1 Nanoparticles Contributing to Other Immunotherapies Efficiency

2.2 Benefits Associated with Combining Nanotechnology to Artificial Immune Modulation

3. Synthetic Immunology to Engineer Antigen Presenting Cells

3.1 Synthetic Immunology for Already Available Immunotherapy

3.2 Eligibility and Applications of Synthetic Immunology in Artificial Immune Modulation

4. Artificial Immune Modulations for Various Indications

4.1 Immunity – Cancer Cycle Relationship

4.2 Influence of Artificial Immune Modulation Over Cancer

4.3 Influence of Artificial Immune Modulation Against Other Indications

5. T-Cell Enrichment and Expansion (E+E) Technology for Proprietary Artificial Immune Modulation Platform

6. NexImmune Clinical Trials for Artificial Immune Modulation Products

6.1 NEX-001 and NEX-003 for Acute Myeloid Leukemia

6.1.1 Overview

6.1.2 Clinical Insight

6.2 NEX-002 for Multiple Myeloma

6.2.1 Overview

6.2.2 Clinical Insight

7. Recent Trends and Opportunities Available for Expansion of Artificial Immune Modulation Therapy

7.1 Globe Cancer Statistics

7.2 Increasing Popularity of Immunotherapy Treatments

7.3 High Adaptability by Pharmaceutical Companies

7.4 Immunotherapy in Combination with Other Cancer Treatment Methods

8. Estimated Commercial Opportunity for Artificial Immune Modulation Drugs

8.1 Immunotherapies and Price Study for Estimating Artificial Immune Modulation Products Commercial Success

8.1.1 CAR-T Cell Therapy and their Products

8.1.2 Tumor-Infiltrating Lymphocyte Immunotherapy

8.2 AIM Therapy Price Estimates

9. Drivers and Challenges Triggered with the Outcome of Artificial Immune Modulation

9.1 Drivers for Artificial Immune Modulation

9.2 Challenges for Artificial Immune Modulation

10. Future Directions for Artificial Immune Modulation

10.1 Exploring New Avenues for Immunotherapy

10.2 Future Regional Landscape for Artificial Immune Modulation

11. Competitive Landscape



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の人工免疫調節療法市場(~2026):市場機会・臨床試験インサイト]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆